Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$7.14 USD
+0.23 (3.33%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $7.14 0.00 (0.00%) 6:26 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
TNGX 7.14 +0.23(3.33%)
Will TNGX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TNGX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TNGX
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?
TNGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
Other News for TNGX
BOXER CAPITAL, LLC Expands Stake in Tango Therapeutics Inc
Tango Therapeutics: A Buy Rating on PRMT5 Inhibitor Prospects and Upcoming Clinical Data
12 Health Care Stocks Moving In Thursday's After-Market Session
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
Barclays Issues a Buy Rating on Tango Therapeutics (TNGX)